Oslo Cancer Cluster (OCC) Incubator relaunches the programme for start-ups in cancer innovation under the new name OCC Accelerator.
OCC Accelerator will identify, select, and develop promising innovations that will improve the lives of cancer patients, reports Sofia Lindén, Oslo Cancer Cluster. The aim is to make the projects attractive for private and public investments.
“This programme is for the best research projects and start-ups with innovative technology in cancer and a strong commercial potential. It is publicly funded with the overarching goal to build Norwegian health industry,” said Bjørn Klem, general manager, Oslo Cancer Cluster Incubator.
OCC Accelerator is a programme led by Oslo Cancer Cluster Incubator and it is funded by Siva.
“We tailor our services according to each company’s needs.”
OCC Incubator regularly meet with researchers, founders, and entrepreneurs to discuss whether their ideas have commercial potential. After a comprehensive evaluation and approval from the board, the project or start-up may be admitted to the OCC Accelerator programme, states Oslo Cancer Cluster.
“We tailor our services according to each company’s needs. Some companies need help with a specific challenge, while others need support with everything during the start-up phase,” says Bjørn Klem.
The activities often include to establish the company, secure intellectual property rights, fund the company, set up development plans, and recruit management, advisors, consultants, and a board of directors. For most companies the most important thing is to pursue equity investments and public funding. OCC Incubator helps the company navigate the complex landscape of funding grants, coach them before negotiations with potential investors and provide valuable contacts.
The global network through Oslo Cancer Cluster also gives the companies exposure through international partnering conferences, pitching events and official communication channels. Moreover, the OCC Accelerator companies have access to the OCC Incubator’s laboratories and offices in Oslo Cancer Cluster Innovation Park.
The companies may stay up to 4 years in the programme. Their progress is evaluated on a yearly basis to ensure they reach the necessary milestones.
Source: Oslo Cancer Cluster
Photo of Bjørn Klem: Stig Jarnes